Journal: Antimicrobial Agents and Chemotherapy

Article Title: The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model

doi: 10.1128/AAC.01682-18

Figure Lengend Snippet: Monotherapy evaluations of fosfomycin and meropenem against P. aeruginosa PAO1 in the HFIM. Panels A to E.

Article Snippet: Fosfomycin disodium salt (fosfomycin for injection, Zolyd; Zavante Therapeutics, recently acquired by Nabriva Therapeutics) was used for the susceptibility testing, preparation of resistance-selecting plates, bioanalytical methods (liquid chromatography/tandem mass spectrometry [LC-MS/MS]) and as medium for the hollow-fiber infection model studies.

Techniques:

Journal: Antimicrobial Agents and Chemotherapy

Article Title: The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model

doi: 10.1128/AAC.01682-18

Figure Lengend Snippet: Combination therapy with fosfomycin and meropenem against P. aeruginosa PAO1. Panels F to I.

Article Snippet: Fosfomycin disodium salt (fosfomycin for injection, Zolyd; Zavante Therapeutics, recently acquired by Nabriva Therapeutics) was used for the susceptibility testing, preparation of resistance-selecting plates, bioanalytical methods (liquid chromatography/tandem mass spectrometry [LC-MS/MS]) and as medium for the hollow-fiber infection model studies.

Techniques:

Journal: Antimicrobial Agents and Chemotherapy

Article Title: The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model

doi: 10.1128/AAC.01682-18

Figure Lengend Snippet: Parameter estimates for all parameters for the combination of meropenem plus fosfomycin against Pseudomonas aeruginosa

Article Snippet: Fosfomycin disodium salt (fosfomycin for injection, Zolyd; Zavante Therapeutics, recently acquired by Nabriva Therapeutics) was used for the susceptibility testing, preparation of resistance-selecting plates, bioanalytical methods (liquid chromatography/tandem mass spectrometry [LC-MS/MS]) and as medium for the hollow-fiber infection model studies.

Techniques:

Journal: Antimicrobial Agents and Chemotherapy

Article Title: The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model

doi: 10.1128/AAC.01682-18

Figure Lengend Snippet: Predicted-observed regressions for pre-Bayesian (population) and Bayesian (individual) analyses for (A) meropenem concentrations, (B) fosfomycin concentrations, (C) total bacterial burden, (D) meropenem-resistant bacterial burden, and (E) fosfomycin-resistant bacterial burden.

Article Snippet: Fosfomycin disodium salt (fosfomycin for injection, Zolyd; Zavante Therapeutics, recently acquired by Nabriva Therapeutics) was used for the susceptibility testing, preparation of resistance-selecting plates, bioanalytical methods (liquid chromatography/tandem mass spectrometry [LC-MS/MS]) and as medium for the hollow-fiber infection model studies.

Techniques:

Journal: Antibiotics

Article Title: Antimicrobial Resistance, Biofilm Formation, and Virulence Genes in Enterococcus Species from Small Backyard Chicken Flocks

doi: 10.3390/antibiotics11030380

Figure Lengend Snippet: Frequency of antimicrobial resistance and MIC values to 10 different antimicrobials for E. faecalis , E. faecium , E. hirae and E. avium isolated from backyard chickens.

Article Snippet: Ten antimicrobials, i.e., vancomycin (VAN, ≥4 μg/mL), erythromycin (ERY, ≥0.5 μg/mL), ampicillin (AMP, ≥8 μg/mL), nitrofurantoin (NIT, ≥32 μg/mL), tetracycline (TET, ≥4 μg/mL), linezolid (LZD, ≥2 μg/mL), chloramphenicol (CHL, ≥8 μg/mL), ciprofloxacin (CIP, ≥1 μg/mL), rifampicin (RIF, ≥1 μg/mL), and fosfomycin (FOS, ≥64 μg/mL) (Merck KGaA, Darmstadt, Germany), were selected for enterococcus antimicrobial sensitivity testing.

Techniques: Isolation